Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.65    0.00 (0.00%)
Bid:
1.55
Ask:
1.75
Spread: 0.20 (12.903%)
Market Cap: £264.66k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Settlement and CVA

30 Aug 2022 18:19

RNS Number : 6596X
Iconic Labs PLC
30 August 2022
 

For immediate release

ICONIC LABS PLC - IN ADMINISTRATION

Settlement of Disputes and Company Voluntary Arrangement

 

The Joint Administrators provide the following update on the administration, settlement of disputes and convening of a General Meeting:

Disputes with D sefton & Greencastle MediA

A Settlement Agreement has been entered into between the Company, Greencastle Media, Arch Capital Partners LLP, Mr D Sefton and the European High Growth Opportunities Securitization Fund. As a result, all litigation proceedings have been dismissed, and all claims, counter claims, including defamation claims, among the parties, have been waived or will be waived upon the CVA being approved.

 

A separate announcement has been issued relating to the retraction of claims made against David Sefton and the former directors of Iconic Labs PLC.

 

COMPANY VOLUNTRAY ARRANGEMENT PROPOSALS

Company Voluntary Arrangement ("CVA") Proposals have been finalised and are being sent out to all creditors and shareholders, together with Notices of Meetings of creditors and shareholders to consider the CVA which to be held on 22 September 2022, at 10.30 am and 2.00pm respectively. The General Meeting of Shareholders will include a Resolution to approve the CVA will be held at the offices of KWM Europe LLP, 9th Floor, 24 Monument Street, London, EC3R 8AJ. The meeting of shareholders will, if the CVA is passed, consider, in addition to a resolution to approve the CVA, resolutions to authorise the directors of the Company to allot shares and to disapply statutory pre-emption rights. These resolutions relating to the issuance of shares by the Company will be crucial to the Company's ability to raise future finance, including from the European High Growth Opportunities Securitization Fund as part of the "future funding" as described below.

A Form of Proxy must be completed, signed and received by Company's registrar, SLC Registrars, in accordance with the shareholders' circular.

 

FUTURE FUNDING

Subject to the CVA being approved and other resolutions being passed by shareholders at the General Meeting, the European High Growth Opportunities Securitization Fund have agreed to provide funding for the CVA and general working capital purposes, under existing and new facilities, subject to certain conditions precedent.

 

RE-LISTING OF SHARES

If the CVA is approved, the Board will enter into discussions with the Financial Conduct Authority with a view to the Company's suspension of shares being lifted. The Company's annual accounts for the year ended 30 June 2021 have been prepared and once audited will be published along with interim accounts to 31 December 2021.

 

ADMINISTRATION

If the CVA is approved, it is anticipated that the Administration will be brought to an end as soon as is practically possible.

 

 

30 August 2022

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDAFMSEESELA
Date   Source Headline
6th Jan 20238:10 amRNSCorporate Update
3rd Jan 20234:48 pmRNSAnnual Financial Report 2022
29th Dec 20223:58 pmRNSFinal Results 2021
22nd Dec 20229:02 amRNSFinancing Facility
16th Dec 20227:00 amRNSRegulatory Approval
14th Dec 20226:31 pmRNSDirectorate Change
30th Nov 202211:15 amRNSConversion of Securities
1st Nov 20224:50 pmRNSSubscription of convertible notes
22nd Sep 20225:59 pmRNSResults of Creditors and General Meetings
30th Aug 20226:19 pmRNSSettlement and CVA
23rd Aug 20224:57 pmRNSRetraction of claims
8th Jun 20226:05 pmRNSAdministration & proposed CVA update
8th Dec 20216:21 pmRNSResults of General Meeting
26th Nov 202110:05 amRNSAdjournment to the GM
19th Nov 202111:25 amRNSAdjournment to the GM - Replacement
18th Nov 20214:00 pmRNSAdjournment to the GM
15th Nov 20214:54 pmRNSAdjournment of General Meeting
7th Oct 202110:33 amRNSGeneral Meeting – Further adjournment
25th Aug 20212:44 pmRNSNOTICE OF APPROVAL OF ADMINISTRATORS' PROPOSALS
12th Aug 20211:22 pmRNSGM update and adjournment notice
13th Jul 20216:38 pmRNSGM update and adjournment notice
1st Jul 20214:48 pmRNSGM update and adjournment notice
16th Jun 20214:56 pmRNSAnnouncement of resignation of directorship
15th Jun 20214:27 pmRNSUpdate on General Meeting
7th Jun 20217:30 amRNSSuspension - Iconic Labs Plc
4th Jun 20216:39 pmRNSAppointment of Administrators
1st Jun 20219:05 amRNSSecond Price Monitoring Extn
1st Jun 20219:00 amRNSPrice Monitoring Extension
26th May 20214:55 pmRNSDirectorate Change
24th May 20212:06 pmRNSSecond Price Monitoring Extn
24th May 20212:00 pmRNSPrice Monitoring Extension
24th May 202111:05 amRNSSecond Price Monitoring Extn
24th May 202111:00 amRNSPrice Monitoring Extension
24th May 20219:36 amRNSDirectorate Change
24th May 20219:05 amRNSSecond Price Monitoring Extn
24th May 20219:00 amRNSPrice Monitoring Extension
21st May 20217:00 amRNSNotice of GM
20th May 202111:05 amRNSSecond Price Monitoring Extn
20th May 202111:00 amRNSPrice Monitoring Extension
19th May 20214:00 pmRNSDirectorate Change
10th May 202111:05 amRNSSecond Price Monitoring Extn
10th May 202111:00 amRNSPrice Monitoring Extension
10th May 20219:05 amRNSSecond Price Monitoring Extn
10th May 20219:00 amRNSPrice Monitoring Extension
10th May 20218:12 amRNSLetter of Intent Signed : Sting Industries
4th May 20214:41 pmRNSSecond Price Monitoring Extn
4th May 20214:36 pmRNSPrice Monitoring Extension
4th May 20212:06 pmRNSSecond Price Monitoring Extn
4th May 20212:01 pmRNSPrice Monitoring Extension
30th Apr 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.